Table 2.
Avanafil (n = 108) | Sildenafil (n = 103) | P‐value | |
---|---|---|---|
End of week 4 | |||
Orgasmic function | 3.1 ± 2.0 (2.7–3.5) | 2.3 ± 2.0 (1.9–2.7) | <0.01 |
Sexual desire | 2.0 ± 1.8 (1.6–2.3) | 1.5 ± 1.9 (1.2–1.9) | 0.08 |
Intercourse satisfaction | 4.0 ± 2.8 (3.5–4.6) | 3.6 ± 2.9 (3.1–4.2) | 0.28 |
Overall satisfaction | 2.7 ± 2.0 (2.3–3.1) | 2.3 ± 2.0 (1.9–2.7) | 0.11 |
End of week 8 | |||
Orgasmic function | 4.1 ± 1.8 (3.8–4.5) | 3.5 ± 1.9 (3.2–3.9) | 0.02 |
Sexual desire | 3.1 ± 1.8 (2.8–3.5) | 2.6 ± 1.9 (2.2–3.0) | 0.03 |
Intercourse satisfaction | 5.4 ± 2.7 (4.9–6.0) | 4.8 ± 2.9 (4.3–5.4) | 0.11 |
Overall satisfaction | 4.2 ± 1.9 (3.8–4.5) | 3.5 ± 2.1 (3.1–3.9) | 0.02 |
End of week 12 | |||
Orgasmic function | 4.7 ± 1.8 (4.3–5.0) | 4.1 ± 2.1 (3.7–4.5) | 0.02 |
Sexual desire | 3.6 ± 1.9 (3.3–4.0) | 3.1 ± 2.1 (2.7–3.5) | 0.04 |
Intercourse satisfaction | 6.2 ± 2.6 (5.7–6.6) | 5.5 ± 3.1 (4.9–6.1) | 0.07 |
Overall satisfaction | 4.8 ± 1.8 (4.5–5.2) | 4.1 ± 2.3 (3.7–4.6) | 0.01 |
Data expressed as mean ± SD (95% CI). All scores are change as compared with baseline. P‐value based on unpaired t‐test.